Journal of hematology and oncology, 2012-10, Vol.5 (1), p.64-64, Article 64
2012
Details
- Autor(en) / Beteiligte
- Titel
- Novel CD20 monoclonal antibodies for lymphoma therapy
- Ist Teil von
- Journal of hematology and oncology, 2012-10, Vol.5 (1), p.64-64, Article 64
- Ort / Verlag
- England: BioMed Central Ltd
- Erscheinungsjahr
- 2012
- Link zum Volltext
- Quelle
- SpringerLink (Online service)
- Beschreibungen/Notizen
- Rituximab (RTX), a monoclonal antibody (mAb) against CD20, has been widely used for lymphoma therapy. RTX in combination with cyclophosphamide /doxorubicin /vincristine /prednisone (R-CHOP) remains the standard frontline regimen for diffuse large B-cell lymphoma. However, suboptimal response and /or resistance to rituximab have remained a challenge in the therapy of B-cell non-Hodgkin's lymphoma (NHL). Novel agents are under active clinical trials. This review will summarize the latest development in new mAbs against CD20, which include second-generation mAbs, ofatumumab, veltuzumab (IMMU-106), ocrelizumab (PRO70769), and third-generation mAbs, AME-133v (ocaratuzumab), PRO131921 and GA101 (obinutumumab).
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1756-8722eISSN: 1756-8722DOI: 10.1186/1756-8722-5-64Titel-ID: cdi_doaj_primary_oai_doaj_org_article_54ad170b4f7444b9ac966409b7518ba6
- Format
- –
- Schlagworte
- Antibodies, Monoclonal - administration & dosage, Antibodies, Monoclonal - immunology, Antibodies, Monoclonal - therapeutic use, Antigens, CD20 - immunology, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, B cells, Binding sites, Biopharmaceutics, Cancer, Care and treatment, Chemotherapy, Clinical trials, Cyclophosphamide, Cytotoxicity, Dosage and administration, Drug dosages, Drug therapy, Health aspects, Hematology, Hospitals, Humans, Lymphoma, Lymphoma, Non-Hodgkin - drug therapy, Lymphoma, Non-Hodgkin - immunology, Lymphomas, Monoclonal antibodies, Non-Hodgkin's lymphomas, Oncology, Patient outcomes, Review